IR News 2021

Nippon Shinyaku Publicly Declares Its Support for the Task Force on Climate-related Financial Disclosures (TCFD) Recommendations

Zogenix Submission of New Drug Application for ZX008 (Fenfluramine Hydrochloride) in Japan

Coverage in NHI Drug Price Listing and Launch Date of TADALAFIL Tablets 2.5 mg/5 mg ZA "SIOE"

Nippon Shinyaku Implements VILTEPSO Managed Access Program

Addition of Viltepso to the List of Injection Drugs That Physicians Providing Health Insurance Treatment Can Administer

Nippon Shinyaku enter into an Option Agreement for DYN101 in Japan

Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2021

Nippon Shinyaku Establishes a Local Subsidiary in China

Notice on the Selection to Apply to New Market Segment “Prime Market” on the Tokyo Stock Exchange

VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the Child Neurology Society Annual Meeting

VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the World Muscle Society 2021 Virtual Conference

MHLW approval of Uptravi® for the Treatment of inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) or persistent/recurrent CTEPH after surgery

Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2021

(Media)Nippon Shinyaku Initiates Litigation Against Sarepta

VILTEPSO® (viltolarsen) injection: Long-Term Efficacy and Safety Data Presented at the PPMD 2021 Virtual Annual Conference

Submission of New Drug Application for NS-065/NCNP-01 (viltolarsen) in China

Webcast of VILTEPSO® (viltolarsen) injection: Long-Term Data Scheduled for Presentation at the PPMD 2021 Virtual Annual Conference

Outline of Consolidated Financial Results for the Year Ended March 31, 2021

(Media)VILTEPSO injection Long-Term Clinical Trial Data to be Presented at the PPMD 2021 Virtual Annual Conference

(Media)MHLW approval of Vidaza(azacitidine) for the Treatment of Acute Myeloid Leukemia

(Media)Nippon Shinyaku and Menarini Group enter into an Exclusive License Agreement to Develop and Commercialize tagraxofusp in Japan

(Media)Nippon Shinyaku Announces Changes to Representative Directors and Members of the Board

Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2020